AXGT - Axovant under pressure after selectively reporting gene therapy data in Parkinson's

Axovant Gene Therapies (AXGT) announces six-month follow-up data from the second cohort of Parkinson's disease ((PD)) patients who have received gene therapy AXO-Lenti-PD in the open-label, dose-escalation Phase 2 clinical trial, SUNRISE-PD.Two evaluable participants showed a 40% improvement in a PD symptom scale called UPDRS III. Two others were unable to participate in the assessment. The status of the two remaining subjects in the cohort (n=6) is not disclosed.Diary "good ON time" (sum of ON time without dyskinesias and ON time with non-troublesome dyskinesias) improved by an average 2.2 hours from baseline across the four patients.The two evaluable patients showed an average 14-point improvement in UPDRS Part II "OFF" score from baseline.In June, it announced six-month follow-up results from the first dose cohort (n=6) that showed an average improvement of 29% in UPDRS III.The company will provide another update at its Parkinson's R&D Day event on Friday, October 30.Shares down 13% premarket

For further details see:

Axovant under pressure after selectively reporting gene therapy data in Parkinson's